Annovis Bio, Inc.

US$0.84As of Sun 8 Nov 2026, 12:00 UTC
NYSE:ANVSHealthcare
Country USA
PE (Fwd) •••
TSR 7Y CAGR (26.05%)
Div yield —
ROE (703.68%)
Biotechnology
Beta (5Y) 1.35
PE TTM —
TSR TTM (59.77%)
Mkt cap US$52.40M
ROIC (439.86%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$0.93
10.09%
(86.18%)
Hold 11|1|9|12|2
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.01
0.01
0.01
0.01
14.25%
25.28%
32.29%
13.26%
Revenue$M
5.284
5.355
5.459
5.649
6.55%
6.83%
7.00%
7.20%
Peers (US$52.40M)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
1.288
(0.153)
(0.139)
EBIT/Intx
0.614
0.190
0.208
Own earn%
(718.15)
(162.71)
(146.55)
Sh yield%
25.23
30.92
31.69
Owners
Insiders/Inst%
8.73
51.74
Short interest%
4.98
SBC / revenue%
2.71
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
12
Op margin range%
4–11
$1 testx
−0.5
Incr. ROIC%
17